However, the RTOG 0320 trial did not show any additional benefit of temozolomide or erlotinib when added to WBRT and SRS in patients with NSCLC with one to three brain metastases [51]
However, the RTOG 0320 trial did not show any additional benefit of temozolomide or erlotinib when added to WBRT and SRS in patients with NSCLC… Read More »However, the RTOG 0320 trial did not show any additional benefit of temozolomide or erlotinib when added to WBRT and SRS in patients with NSCLC with one to three brain metastases [51]